ZPL-3893787 30 mg, an oral selective H4R antagonist (Figure 3b and Figure 4b) given once a day for 8 weeks, has been shown to exert anti-inflammatory effects over placebo in patients with physician-documented moderate-to-severe AD [108]. This evidence concerns the gene HRH4 and Alzheimer disease.